PeptideDB

Phthalazinone pyrazole 880487-62-7

Phthalazinone pyrazole 880487-62-7

CAS No.: 880487-62-7

Phthalazinone pyrazole is a potent, selective, orally bioactive Aurora-Kinase inhibitor (antagonist) with IC50 of 0.031
Data collection:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

Phthalazinone pyrazole is a potent, selective, orally bioactive Aurora-Kinase inhibitor (antagonist) with IC50 of 0.031 μM. Phthalazinone pyrazole blocks mitosis and subsequently inhibits tumor growth through apoptosis of proliferating cells. Phthalazinone pyrazole inhibits epithelial-mesenchymal transition (EMT) during the differentiation of human embryonic stem cells into hepatocyte-like cells (HLC).

Physicochemical Properties


Molecular Formula C18H15N5O
Molecular Weight 317.344602823257
Exact Mass 317.127
Elemental Analysis C, 68.13; H, 4.76; N, 22.07; O, 5.04
CAS # 880487-62-7
Related CAS # 880487-62-7;
PubChem CID 11652621
Appearance Brown to gray solid powder
Density 1.4±0.1 g/cm3
Boiling Point 557.7±52.0 °C at 760 mmHg
Flash Point 291.1±30.7 °C
Vapour Pressure 0.0±1.5 mmHg at 25°C
Index of Refraction 1.716
LogP 3.03
Hydrogen Bond Donor Count 2
Hydrogen Bond Acceptor Count 3
Rotatable Bond Count 3
Heavy Atom Count 24
Complexity 502
Defined Atom Stereocenter Count 0
SMILES

O=C1N(C2C=CC=CC=2)N=C(NC2C=C(C)NN=2)C2C1=CC=CC=2

InChi Key DSDIWWSXOOXFSI-UHFFFAOYSA-N
InChi Code

InChI=1S/C18H15N5O/c1-12-11-16(21-20-12)19-17-14-9-5-6-10-15(14)18(24)23(22-17)13-7-3-2-4-8-13/h2-11H,1H3,(H2,19,20,21,22)
Chemical Name

4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-phenylphthalazin-1-one
Synonyms

Phthalazinone pyrazole
HS Tariff Code 2934.99.9001
Storage

Powder-20°C 3 years

4°C 2 years

In solvent -80°C 6 months

-20°C 1 month

Note: This product requires protection from light (avoid light exposure) during transportation and storage.
Shipping Condition Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity


Targets Aurora-A (IC50 = 0.031 μM)
ln Vitro Phthalazinone pyrazole (1 and 10 μM; 30 hours) increases the ability of HLCs to proliferate[2].
Phthalazinone pyrazole (1, 10, and 100 μM; 5 days) increases the morphological changes of the liver in differentiated HLCs without causing cytotoxicity[2].
Phthalazinone pyrazole (1 and 10 μM; 5 and 17 days) inhibits the AKT signaling pathway through an off-target effect and concurrent upregulation of HNF4α, rather than directly inhibiting Aurora-A, which suppresses the EMT and induces maturation of HLCs. Western blot and qPCR are used to confirm the outcome[2].
References

[1]. Phthalazinone pyrazoles as potent, selective, and orally bioavailable inhibitors of Aurora-A kinase. J Med Chem. 2011;54(1):312-319.

[2]. Phthalazinone Pyrazole Enhances the Hepatic Functions of Human Embryonic Stem Cell-Derived Hepatocyte-Like Cells via Suppression of the Epithelial-Mesenchymal Transition. Stem Cell Rev Rep. 2018;14(3):438-450.


Solubility Data


Solubility (In Vitro) DMSO: ≥ 11.11 mg/mL (~35.0 mM)
Solubility (In Vivo) Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.

Injection Formulations
(e.g. IP/IV/IM/SC)
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution 50 μL Tween 80 850 μL Saline)
*Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution.
Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO 400 μLPEG300 50 μL Tween 80 450 μL Saline)
Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO 900 μL Corn oil)
Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals).
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO 900 μL (20% SBE-β-CD in saline)]
*Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.
Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin 500 μL Saline)
Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO 100 μLPEG300 200 μL castor oil 650 μL Saline)
Injection Formulation 7: Ethanol : Cremophor : Saline = 10: 10 : 80 (i.e. 100 μL Ethanol 100 μL Cremophor 800 μL Saline)
Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline
Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH 900 μL Corn oil)
Injection Formulation 10: EtOH : PEG300:Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH 400 μLPEG300 50 μL Tween 80 450 μL Saline)

Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium)
Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose
Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals).
Oral Formulation 3: Dissolved in PEG400
Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose
Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose
Oral Formulation 6: Mixing with food powders

Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 3.1512 mL 15.7560 mL 31.5119 mL
5 mM 0.6302 mL 3.1512 mL 6.3024 mL
10 mM 0.3151 mL 1.5756 mL 3.1512 mL
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.